Sign Up Today and Learn More About Metacrine Stock
Invest in or calculate the value of your shares in Metacrine or other pre-IPO companies through EquityZen's platform.
Metacrine Stock
Metacrine is a privately held biotech company
About Metacrine Stock
Founded
2015
Headquarters
San Diego, CA, US
Total Funding
123M
Industries
Software, Artificial Intelligence, Financial Services
Metacrine is a privately held biotech company 
founded in 2015 on technology licensed from the 
laboratory of Dr. Ronald Evans, a world leader in
 nuclear hormone receptors and Howard Hughes
Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.
Metacrine Press Mentions
Stay in the know about the latest news on Metacrine
Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist
GlobeNewswire (press release) • Jun 13, 2018
Metacrine Completes $65M Series C Financing
FinSMEs (blog) • Jun 08, 2018
Metacrine to Present at 30th Annual ROTH Conference and HC Wainwright & Co. 2nd Annual NASH Investor Conference
PR Newswire (press release) • Mar 07, 2018
Metacrine raises $22M to advance liver drug for humans
The San Diego Union-Tribune • Dec 07, 2017
Investors in Metacrine
Discover investors in Metacrine stock and explore their portfolio companies
Metacrine Management
Leadership team at Metacrine
CEO
Neil McDonnell
CFO
Trisha Millican
Join now and verify your accreditation status to gain access to:
- Metacrine Current Valuation
- Metacrine Stock Price
- Metacrine Management
- Available deals in Metacrine and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Metacrine Cap Table and Funding History by Share Class and Liquidity Preferences
- Metacrine Revenue and Financials
- Metacrine Highlights
- Metacrine Business Model
- Metacrine Risk Factors
- Metacrine Research Report from SACRA Research
Trading Metacrine Stock
How to invest in Metacrine stock?
Accredited investors can buy pre-IPO stock in companies like Metacrine through EquityZen funds. These investments are made available by existing Metacrine shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Metacrine stock?
Shareholders can sell their Metacrine stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."